manufacturing defects – Page 43

Disintegration time failure after tooling change – process vs formulation assessment

Addressing Disintegration Time Failures Following Tooling Changes in Tablet Manufacturing In the world of pharmaceutical manufacturing, consistent product quality is critical. When faced with disintegration time failures following tooling changes,…

Hardness drift after scale-up – FDA inspection observation risk

Addressing Hardness Drift After Scale-Up: An Investigation Approach to FDA Inspection Risks Hardness drift after scale-up is a critical manufacturing defect that can lead to Out of Specification (OOS) results…

Tablet chipping complaint after scale-up – root cause analysis breakdown

Root Cause Analysis of Tablet Chipping Complaints Following Scale-Up During pharmaceutical manufacturing, scaling up production can sometimes lead to unexpected complications, such as increased instances of tablet chipping. This can…

Tablet lamination defect after tooling change – root cause analysis breakdown

Analyzing Tablet Lamination Defects Following Tooling Changes In pharmaceutical manufacturing, discrepancies can significantly impact quality control (QC) and overall product efficacy. One common concern is a tablet lamination defect observed…

Tablet lamination defect during campaign changeover – process vs formulation assessment

Addressing Tablet Lamination Defects During Changeover: A Comprehensive Investigation Guide In the high-stakes environment of pharmaceutical manufacturing, defects such as tablet lamination can pose significant challenges, especially during campaign changeovers.…

Sticking and picking after tooling change – CAPA failure identified

Understanding Sticking and Picking Issues Following Tooling Changes in Pharmaceutical Manufacturing In the world of pharmaceutical manufacturing, deviations from standard production processes can lead to significant quality concerns and regulatory…

Disintegration time failure during high-speed runs – root cause analysis breakdown

Understanding and Investigating Disintegration Time Failures during High-Speed Runs In pharmaceutical manufacturing, ensuring that tablets meet stringent disintegration time specifications is crucial for product efficacy and consumer safety. A failure…

Weight variation failure during campaign changeover – FDA inspection observation risk

Addressing Weight Variation Failures During Campaign Changeover: An Investigation Framework Weight variation failures during campaign changeover pose a significant risk in pharmaceutical manufacturing. Such incidents can result in non-compliance with…

Tablet chipping complaint after tooling change – process vs formulation assessment

Investigating Tablet Chipping Complaints Following Tooling Adjustments in Manufacturing In the realm of pharmaceutical manufacturing, product quality is non-negotiable. A recent incident involving tablet chipping complaints after a tooling change…

Disintegration time failure during high-speed runs – FDA inspection observation risk

Investigating Disintegration Time Failures During High-Speed Tablet Runs Frequent disintegration time failures during high-speed tablet manufacturing not only jeopardize batch quality but also raise concerns during regulatory inspections. This article…

Tablet capping observed during high-speed runs – process vs formulation assessment

Investigating Tablet Capping Events During High-Speed Production Runs Tablet capping is a critical manufacturing defect characterized by the separation or detachment of the tablet cap from the body during the…

Recurring Manufacturing Defects? Root Cause Patterns and Fixes That Prevent Product Failures

Addressing Recurring Manufacturing Defects: Identifying Root Causes and Implementing Solutions Pharmaceutical manufacturing often faces challenges that can lead to defects and product failures, potentially impacting quality and compliance. This article…